NIH Genomics Licensing Policy Guidance Debated By Advocacy Groups
This article was originally published in The Gray Sheet
Executive SummaryThe National Institutes of Health expects to publish by year-end a "best practices" document for the licensing of genomic inventions
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.